On Sunday, the German company Bayer said that it has begun a Phase III trial programme to examine the effectiveness and security of asundexian, an oral Factor XIa (FXIa) inhibitor.
According to Bayer, the medication candidate has the potential to provide a novel therapy option for people with atrial fibrillation, non-cardioembolic ischemic strokes, and high-risk transient ischemic attacks.
Around 2026, the patent on Bayer’s top-selling Xarelto, a medication that prevents strokes and in which partner Johnson & Johnson holds some rights, will expire.
Post Your Comments